SG11201704519YA - Methods and compositons for treating cancer - Google Patents
Methods and compositons for treating cancerInfo
- Publication number
- SG11201704519YA SG11201704519YA SG11201704519YA SG11201704519YA SG11201704519YA SG 11201704519Y A SG11201704519Y A SG 11201704519YA SG 11201704519Y A SG11201704519Y A SG 11201704519YA SG 11201704519Y A SG11201704519Y A SG 11201704519YA SG 11201704519Y A SG11201704519Y A SG 11201704519YA
- Authority
- SG
- Singapore
- Prior art keywords
- compositons
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086346P | 2014-12-02 | 2014-12-02 | |
| PCT/US2015/063267 WO2016089916A1 (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704519YA true SG11201704519YA (en) | 2017-07-28 |
Family
ID=56078487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704519YA SG11201704519YA (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
| SG10202103475XA SG10202103475XA (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202103475XA SG10202103475XA (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9650428B2 (en) |
| EP (1) | EP3227317A4 (en) |
| JP (1) | JP2017537622A (en) |
| KR (1) | KR20180041087A (en) |
| CN (1) | CN107709353A (en) |
| AR (1) | AR102879A1 (en) |
| AU (1) | AU2015355084A1 (en) |
| BR (1) | BR112017011771A2 (en) |
| CA (1) | CA2969714A1 (en) |
| EA (1) | EA201791210A1 (en) |
| HK (1) | HK1251862A1 (en) |
| IL (1) | IL252610A0 (en) |
| MX (1) | MX2017007272A (en) |
| PH (1) | PH12017501031A1 (en) |
| SG (2) | SG11201704519YA (en) |
| TW (1) | TW201636425A (en) |
| UY (1) | UY36418A (en) |
| WO (1) | WO2016089916A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201704519YA (en) | 2014-12-02 | 2017-07-28 | Roger Williams Hospital | Methods and compositons for treating cancer |
| CN115925971A (en) * | 2015-06-19 | 2023-04-07 | 塞巴斯蒂安·科博尔德 | PD-1-CD28 fusion protein and application thereof in medicine |
| SG11201800872QA (en) * | 2015-08-05 | 2018-03-28 | Yoo Young Pharm Co Ltd | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed |
| WO2018112266A1 (en) * | 2016-12-14 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| CN110612119A (en) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院（Dba西雅图儿童研究所） | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| KR20200100654A (en) * | 2017-11-20 | 2020-08-26 | 프로스펙트 차터케어 알더블유엠씨, 엘엘씨 디/비/에이 로저 윌리암스 메디컬 센터 | Composition for improving CAR-T cell functionality and use thereof |
| CA3089051A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
| CN110144326A (en) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | A kind of antitumor T cell of targeting and its preparation method and application |
| CN110157674A (en) * | 2018-02-12 | 2019-08-23 | 深圳宾德生物技术有限公司 | A kind of targeting T lymphocyte and its preparation method and application |
| CN108440674A (en) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | A kind of Trop-2 specific chimerics antigen receptor cell is prepared and application thereof |
| AU2021342299A1 (en) * | 2020-09-11 | 2023-04-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Compositions and methods of use thereof for prevention and treatment of influenza infections |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN113304267B (en) * | 2021-06-11 | 2022-03-15 | 河南大学 | Therapeutic target of lung cancer and application thereof |
| CN114014941B (en) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | Chimeric antigen receptor targeting IL13R alpha2 and uses thereof |
| CN116549667B (en) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | PAS modified lipid nanoparticle, pharmaceutical preparation containing PAS modified lipid nanoparticle, and preparation method and application of PAS modified lipid nanoparticle |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965126A (en) * | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
| JP2004500047A (en) * | 1999-10-20 | 2004-01-08 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | Chimeric immunogenic compositions and nucleic acids encoding them |
| JP2005518800A (en) * | 2002-03-01 | 2005-06-30 | ブリストル−マイヤーズ スクイブ カンパニー | Transgenic non-human mammal expressing a constitutively activated tyrosine kinase receptor |
| WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| US7709625B2 (en) * | 2004-06-10 | 2010-05-04 | The Board Of Regents Of The University Of Texas | Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy |
| BRPI0520686A2 (en) * | 2005-11-16 | 2009-05-19 | Univ Mexico Nacional Autonoma | use of transcriptome modifying agents associated with cancer chemotherapy or radiotherapy |
| CN101438158A (en) * | 2006-03-06 | 2009-05-20 | 阿穆尼克斯股份有限公司 | Genetic packages and uses thereof |
| US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| PL3006459T3 (en) * | 2008-08-26 | 2022-01-17 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| EP2552959B1 (en) * | 2010-03-26 | 2017-01-11 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| WO2014090985A1 (en) * | 2012-12-13 | 2014-06-19 | Universität Leipzig | T-cell modulation by exon skipping |
| LT2956175T (en) * | 2013-02-15 | 2017-12-11 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
| EP2968601A1 (en) * | 2013-03-10 | 2016-01-20 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| WO2015120363A1 (en) * | 2014-02-10 | 2015-08-13 | Emory University | Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer |
| SG11201704519YA (en) | 2014-12-02 | 2017-07-28 | Roger Williams Hospital | Methods and compositons for treating cancer |
-
2015
- 2015-12-01 SG SG11201704519YA patent/SG11201704519YA/en unknown
- 2015-12-01 BR BR112017011771A patent/BR112017011771A2/en not_active Application Discontinuation
- 2015-12-01 US US14/956,299 patent/US9650428B2/en not_active Expired - Fee Related
- 2015-12-01 MX MX2017007272A patent/MX2017007272A/en unknown
- 2015-12-01 CN CN201580074883.3A patent/CN107709353A/en active Pending
- 2015-12-01 EA EA201791210A patent/EA201791210A1/en unknown
- 2015-12-01 EP EP15865800.5A patent/EP3227317A4/en not_active Withdrawn
- 2015-12-01 CA CA2969714A patent/CA2969714A1/en not_active Abandoned
- 2015-12-01 KR KR1020177018139A patent/KR20180041087A/en unknown
- 2015-12-01 JP JP2017529284A patent/JP2017537622A/en active Pending
- 2015-12-01 AU AU2015355084A patent/AU2015355084A1/en not_active Abandoned
- 2015-12-01 WO PCT/US2015/063267 patent/WO2016089916A1/en active Application Filing
- 2015-12-01 SG SG10202103475XA patent/SG10202103475XA/en unknown
- 2015-12-02 UY UY0001036418A patent/UY36418A/en not_active Application Discontinuation
- 2015-12-02 AR ARP150103939A patent/AR102879A1/en unknown
- 2015-12-02 TW TW104140317A patent/TW201636425A/en unknown
-
2017
- 2017-05-09 US US15/590,961 patent/US20180072789A1/en not_active Abandoned
- 2017-06-01 IL IL252610A patent/IL252610A0/en unknown
- 2017-06-02 PH PH12017501031A patent/PH12017501031A1/en unknown
-
2018
- 2018-08-16 HK HK18110565.4A patent/HK1251862A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201636425A (en) | 2016-10-16 |
| HK1251862A1 (en) | 2019-04-26 |
| MX2017007272A (en) | 2018-06-06 |
| US20180072789A1 (en) | 2018-03-15 |
| UY36418A (en) | 2016-06-30 |
| AR102879A1 (en) | 2017-03-29 |
| EP3227317A1 (en) | 2017-10-11 |
| US20160151490A1 (en) | 2016-06-02 |
| JP2017537622A (en) | 2017-12-21 |
| EP3227317A4 (en) | 2018-04-25 |
| SG10202103475XA (en) | 2021-05-28 |
| KR20180041087A (en) | 2018-04-23 |
| PH12017501031A1 (en) | 2017-11-27 |
| EA201791210A1 (en) | 2017-11-30 |
| AU2015355084A1 (en) | 2017-06-29 |
| WO2016089916A1 (en) | 2016-06-09 |
| CN107709353A (en) | 2018-02-16 |
| CA2969714A1 (en) | 2016-06-09 |
| US9650428B2 (en) | 2017-05-16 |
| IL252610A0 (en) | 2017-07-31 |
| BR112017011771A2 (en) | 2018-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1251862A1 (en) | Methods and compositons for treating cancer | |
| HK1251407A1 (en) | Methods for treating cancer | |
| IL260199B (en) | Methods of treating cancer | |
| IL304820A (en) | Compositions and methods for treating cancer | |
| PT3377516T (en) | Methods and compositions for treating cancer | |
| HK1249469A1 (en) | Methods for treating cancer with rorgamma inhibitors | |
| RS61929B1 (en) | Methods and compositions for treating cancer | |
| HK1254258A1 (en) | Methods for treating cancer using apilimod | |
| EP3177292A4 (en) | Compounds and methods for treating cancer | |
| HK1250944A1 (en) | Methods for treating cancer | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| HK1250942A1 (en) | Methods for treating cancer | |
| IL246558A0 (en) | Novel methods for treating cancer | |
| HK1250943A1 (en) | Methods for treating cancer | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| HK1250958A1 (en) | Compositions and methods for treating cancer | |
| GB201414904D0 (en) | Materials and methods for treating cancer |